Viewing Study NCT05714202

Home

Certify Doc

Genes

Clinical Trials

CompTox

DrugMatrix

Open Targets

Products

Support

Bugs

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-25 @ 3:46 AM

Ignite Modification Date: 2025-12-26 @ 2:33 AM

Study NCT ID: NCT05714202

Status: ACTIVE_NOT_RECRUITING

Last Update Posted: 2025-12-19

First Post: 2023-01-27

Is NOT Gene Therapy: False

Has Adverse Events: False

Brief Title: A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)

Sponsor: Janssen Research & Development, LLC

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module